Rachel L. Dusek

1.6k total citations
27 papers, 1.2k citations indexed

About

Rachel L. Dusek is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rachel L. Dusek has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rachel L. Dusek's work include Wnt/β-catenin signaling in development and cancer (5 papers), Ovarian cancer diagnosis and treatment (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Rachel L. Dusek is often cited by papers focused on Wnt/β-catenin signaling in development and cancer (5 papers), Ovarian cancer diagnosis and treatment (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Rachel L. Dusek collaborates with scholars based in United States, Italy and Spain. Rachel L. Dusek's co-authors include Laura D. Attardi, Kathleen J. Green, Dadi Jiang, Lisa M. Godsel, Spiro Getsios, Colleen A. Brady, Stephano S. Mello, Kathryn T. Bieging, Daniela Kenzelmann Brož and Arend Sidow and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Rachel L. Dusek

24 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachel L. Dusek United States	13	783	325	287	181	148	27	1.2k
Nadem Soufir France	22	877 1.1×	294 0.9×	649 2.3×	243 1.3×	89 0.6×	47	1.7k
Patrizia Sini Austria	13	533 0.7×	247 0.8×	194 0.7×	78 0.4×	56 0.4×	21	917
Alan W. Lau United States	19	1.5k 1.9×	308 0.9×	638 2.2×	169 0.9×	123 0.8×	20	2.1k
Mirentxu Santos Spain	20	855 1.1×	180 0.6×	529 1.8×	112 0.6×	53 0.4×	43	1.3k
Keisuke Nimura Japan	22	1.3k 1.6×	168 0.5×	177 0.6×	174 1.0×	60 0.4×	43	1.8k
Zhilan Hu United States	16	1.3k 1.6×	210 0.6×	262 0.9×	107 0.6×	206 1.4×	25	1.9k
Miki Hashimura Japan	23	731 0.9×	118 0.4×	396 1.4×	134 0.7×	128 0.9×	56	1.4k
Yoshiya Shimao Japan	15	508 0.6×	255 0.8×	350 1.2×	37 0.2×	95 0.6×	43	1.2k
Frédéric Aurade France	20	705 0.9×	213 0.7×	183 0.6×	113 0.6×	40 0.3×	31	1.2k
Rainer Will Germany	19	763 1.0×	114 0.4×	202 0.7×	65 0.4×	138 0.9×	50	1.3k

Countries citing papers authored by Rachel L. Dusek

Since Specialization

Citations

This map shows the geographic impact of Rachel L. Dusek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel L. Dusek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel L. Dusek more than expected).

Fields of papers citing papers by Rachel L. Dusek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel L. Dusek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel L. Dusek. The network helps show where Rachel L. Dusek may publish in the future.

Co-authorship network of co-authors of Rachel L. Dusek

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel L. Dusek. A scholar is included among the top collaborators of Rachel L. Dusek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel L. Dusek. Rachel L. Dusek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Concin, Nicole, Manish R. Patel, Vicky Makker, et al.. (2022). 2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies. International Journal of Gynecological Cancer. 32. A185–A185.

Robillard, Liliane, Mingxiang Liao, Minh Nguyen, et al.. (2022). The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models. Journal of Immunotherapy. 45(8). 335–348. 4 indexed citations

Oaknin, Ana, Floor Backes, Els Van Nieuwenhuysen, et al.. (2022). LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (034). Gynecologic Oncology. 166. S24–S24. 4 indexed citations

Patel, Manish R., Vicky Makker, Ana Oaknin, et al.. (2022). Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).. Journal of Clinical Oncology. 40(16_suppl). 5517–5517. 2 indexed citations

Hamilton, Erika, Manish R. Patel, Kenton Wride, et al.. (2020). 556P Initial clinical experience of lucitanib + nivolumab in advanced metastatic solid tumours: Data from the phase Ib/II LIO-1 study (CO-3810-101; NCT04042116). Annals of Oncology. 31. S480–S481. 2 indexed citations

Concin, Nicole, Sandro Pignata, Philipp Harter, et al.. (2020). 885TiP LIO-1: A phase II study of lucitanib + nivolumab in patients (pts) with gynaecological tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO). Annals of Oncology. 31. S648–S648. 1 indexed citations

Lopes, Jared E., Rachel L. Dusek, Liliane Robillard, et al.. (2020). Abstract 2202: The combination of a mouse ortholog of ALKS 4230, a selective agonist of the intermediate affinity IL-2 receptor, and the angiogenesis inhibitor lucitanib enhances antitumor activity. Cancer Research. 80(16_Supplement). 2202–2202. 2 indexed citations

Grivas, Petros, Nicholas J. Vogelzang, Ajjai Alva, et al.. (2019). ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 37(7_suppl). TPS496–TPS496. 2 indexed citations

Krupka, Christina, Felix S. Lichtenegger, Thomas Köhnke, et al.. (2017). Targeting CD157 in AML using a novel, Fc-engineered antibody construct. Oncotarget. 8(22). 35707–35717. 31 indexed citations

10.

Brož, Daniela Kenzelmann, Stephano S. Mello, Kathryn T. Bieging, et al.. (2013). Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes & Development. 27(9). 1016–1031. 345 indexed citations

11.

Dusek, Rachel L., et al.. (2012). Deficiency of the p53/p63 target Perp alters mammary gland homeostasis and promotes cancer. Breast Cancer Research. 14(2). R65–R65. 22 indexed citations

12.

Dusek, Rachel L. & Laura D. Attardi. (2011). Desmosomes: new perpetrators in tumour suppression. Nature reviews. Cancer. 11(5). 317–323. 148 indexed citations

13.

Beaudry, Veronica G., Dadi Jiang, Rachel L. Dusek, et al.. (2010). Loss of the p53/p63 Regulated Desmosomal Protein Perp Promotes Tumorigenesis. PLoS Genetics. 6(10). e1001168–e1001168. 66 indexed citations

14.

Getsios, Spiro, Cory L. Simpson, Shin-ichiro Kojima, et al.. (2009). Desmoglein 1–dependent suppression of EGFR signaling promotes epidermal differentiation and morphogenesis. The Journal of Cell Biology. 185(7). 1243–1258. 175 indexed citations

15.

Dusek, Rachel L., et al.. (2009). Loss of the Desmosomal Protein Perp Enhances the Phenotypic Effects of Pemphigus Vulgaris Autoantibodies. Journal of Investigative Dermatology. 129(7). 1710–1718. 14 indexed citations

16.

Dusek, Rachel L., Lisa M. Godsel, Feng Chen, et al.. (2006). Plakoglobin Deficiency Protects Keratinocytes from Apoptosis. Journal of Investigative Dermatology. 127(4). 792–801. 33 indexed citations

17.

Dusek, Rachel L., Lisa M. Godsel, & Kathleen J. Green. (2006). Discriminating roles of desmosomal cadherins: Beyond desmosomal adhesion. Journal of Dermatological Science. 45(1). 7–21. 106 indexed citations

18.

Dusek, Rachel L., Spiro Getsios, Feng Chen, et al.. (2005). The Differentiation-dependent Desmosomal Cadherin Desmoglein 1 Is a Novel Caspase-3 Target That Regulates Apoptosis in Keratinocytes. Journal of Biological Chemistry. 281(6). 3614–3624. 89 indexed citations

19.

Getsios, Spiro, Evangeline V. Amargo, Rachel L. Dusek, et al.. (2004). Coordinated expression of desmoglein 1 and desmocollin 1 regulates intercellular adhesion. Differentiation. 72(8). 419–433. 77 indexed citations

20.

Gaudry, Claire A., H. Pałka, Rachel L. Dusek, et al.. (2001). Tyrosine-phosphorylated Plakoglobin Is Associated with Desmogleins but Not Desmoplakin after Epidermal Growth Factor Receptor Activation. Journal of Biological Chemistry. 276(27). 24871–24880. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact